Search Results

You are looking at 31 - 40 of 1,651 items for :

  • "chemotherapy" x
Clear All
Full access

Renata R. Urban, Hao He, Rafael Alfonso-Cristancho, Melissa M. Hardesty and Barbara A. Goff

that they treat. In preparation for payment reform, ASCO developed a bundled payment model for the treatment of patients with cancer using chemotherapy. 2 , 3 Ovarian cancer is a complex disease requiring surgery and chemotherapy to achieve the best

Full access

Alison K. Conlin and Andrew D. Seidman

Genentech Inc. References 1. Early Breast Cancer Trialists' Collaborative Group . Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials . Lancet 2005

Full access

Vivek Verma, Pamela K. Allen, Charles B. Simone II, Hiram A. Gay and Steven H. Lin

malignancies. 5 Moreover, a median overall survival (OS) of 2 to 3 years can be achieved for select patients with oligometastatic M1 NPC receiving palliative chemotherapy and/or those with good response to systemic therapy. 6 – 8 In light of these

Full access

Richard Li, Wei-Hsien Hou, Joseph Chao, Yanghee Woo, Scott Glaser, Arya Amini, Rebecca A. Nelson and Yi-Jen Chen

dissection, has been established as the primary curative treatment modality for locally advanced gastric cancer. 3 , 4 Perioperative chemotherapy, adjuvant chemotherapy, or adjuvant chemoradiation (CRT) are given in conjunction with surgery based on data

Full access

Andrea Cercek, Karyn A. Goodman, Carla Hajj, Emily Weisberger, Neil H. Segal, Diane L. Reidy-Lagunes, Zsofia K. Stadler, Abraham J. Wu, Martin R. Weiser, Philip B. Paty, Jose G. Guillem, Garrett M. Nash, Larissa K. Temple, Julio Garcia-Aguilar and Leonard B. Saltz

those of local recurrence. 1 , 2 The current standard management for stage II (T3/T4N0) and stage III (TanyN1/N2) rectal cancer is neoadjuvant chemoradiotherapy, followed by surgery, with 4 months of adjuvant systemic chemotherapy given at the end. 1

Full access

Jagar Jasem, Christine M. Fisher, Arya Amini, Elena Shagisultanova, Rachel Rabinovitch, Virginia F. Borges, Anthony Elias and Peter Kabos

Background Adjuvant chemotherapy was once considered the standard of care for patients with primary breast cancer with tumors >1 cm regardless of axillary lymph node involvement. 1 – 3 However, given disease recurrence rates of <20% by 10

Full access

Li-Ting Liu, Qiu-Yan Chen, Lin-Quan Tang, Shan-Shan Guo, Ling Guo, Hao-Yuan Mo, Yang Li, Qing-Nan Tang, Xue-Song Sun, Yu-Jing Liang, Chong Zhao, Xiang Guo, Chao-Nan Qian, Mu-Sheng Zeng, Jin-Xin Bei, Ming-Huang Hong, Jian-Yong Shao, Ying Sun, Jun Ma and Hai-Qiang Mai

with concurrent chemotherapy has been shown to be the standard treatment protocol. 4 , 5 Despite the use of concurrent chemotherapy, distant metastasis is still a major component of treatment failures, occurring in 18% to 27% of patients. 5 , 6 To

Full access

Ali A. Mokdad, Rebecca M. Minter, Adam C. Yopp, Matthew R. Porembka, Sam C. Wang, Hong Zhu, Mathew M. Augustine, John C. Mansour, Michael A. Choti and Patricio M. Polanco

Approximately 10% to 20% of patients with pancreatic adenocarcinoma present with resectable disease, and treatment often constitutes resection followed by chemotherapy (CT). 1 – 5 More recently, however, preoperative therapy has been increasing

Full access

Robert E. Glasgow, David H. Ilson, James A. Hayman, Hans Gerdes, Mary F. Mulcahy and Jaffer A. Ajani

significant recent advances in preoperative staging modalities to optimize patient selection for treatment. In addition, treatment algorithms consisting of a combination of chemotherapy, radiation therapy, and surgery have been developed to optimize treatment

Full access

Gary H. Lyman and Marek S. Poniewierski

Neutropenia and its complications represent the major dose-limiting toxicities associated with systemic cancer chemotherapy and is associated with considerable morbidity, mortality, and cost. 1 Neutropenic events may result in dose reductions or